KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Asset Writedowns and Impairment (2022 - 2025)

Historic Asset Writedowns and Impairment for Amgen (AMGN) over the last 3 years, with Q3 2025 value amounting to $400.0 million.

  • Amgen's Asset Writedowns and Impairment rose 55573.77% to $400.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 73023.26%. This contributed to the annual value of $567.0 million for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Amgen's Asset Writedowns and Impairment is $400.0 million, which was up 55573.77% from $800.0 million recorded in Q1 2025.
  • In the past 5 years, Amgen's Asset Writedowns and Impairment ranged from a high of $800.0 million in Q1 2025 and a low of -$129.0 million during Q4 2024
  • For the 3-year period, Amgen's Asset Writedowns and Impairment averaged around $172.4 million, with its median value being $61.0 million (2024).
  • Examining YoY changes over the last 5 years, Amgen's Asset Writedowns and Impairment showed a top increase of 107647.06% in 2025 and a maximum decrease of 55573.77% in 2025.
  • Over the past 3 years, Amgen's Asset Writedowns and Impairment (Quarter) stood at $2.0 million in 2022, then plummeted by 6550.0% to -$129.0 million in 2024, then skyrocketed by 410.08% to $400.0 million in 2025.
  • Its Asset Writedowns and Impairment stands at $400.0 million for Q3 2025, versus $800.0 million for Q1 2025 and -$129.0 million for Q4 2024.